Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.~* Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis~Exclusion Criteria:~* Subject had previously received systemic or biologic anti-IL-12 therapy~* Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy~* Subject is taking or requires oral or injectable corticosteroids~* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study~* Female subject who is pregnant or breast-feeding or considering becoming pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Anti IL-12 monoclonal antibody/ABT-874, up to 12 weeks, 200 mg every week for 12 weeks
- 2 (Type: ACTIVE_COMPARATOR): Anti IL-12 monoclonal antibody/ABT-874, 200 mg QOW for 12 weeks
- 3 (Type: ACTIVE_COMPARATOR): Anti IL-12 monoclonal antibody/ABT-874, 100 mg QOW in 12 weeks
- 4 (Type: ACTIVE_COMPARATOR): Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 4 doses in 12 weeks
- 5 (Type: ACTIVE_COMPARATOR): Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 1 dose in 12 weeks
- 6 (Type: PLACEBO_COMPARATOR): placebo, 12 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).